Figure 12. Schematic illustration showing the proposed N-alkyl interaction sites, A and B in relation to the structure of the template molecule (S)-octoclothepin. A is the site proposed to be used by the alkyl group in compounds with an N-ethyl substituent, while B is the proposed site for an N-benzyl substituent.

interaction model proposed by Liljefors and Bøgesø, extending this model to include the important benzamide class of DA D-2 receptor antagonists. For benzamides with an acyclic amide side chain, the most probable receptor-bound conformation is the one with an extended alkyl substituent. The enantioselectivity of the chiral benzamide of type **3** may be rationalized in terms of conformational energy differences for the receptor bound enantiomers. The N-alkyl substituent of the benzamides is proposed to be able to interact with two different sites for the N-alkyl substituent. For the benzamides studied in this work, the N-benzyl groups of compounds **6** and **12** are proposed to interact with one receptor site, while the alkyl group in benzamides with a N-ethyl group (compounds **9**, **10**, and **11**) may interact with the other site.

2-Alkynyl Derivatives of Adenosine and Adenosine-5'-N-ethyluronamide as Selective Agonists at A2 Adenosine Receptors[1]

Gloria Cristalli,* Alessandra Eleuteri, Sauro Vittori, Rosaria Volpini, Martin J. Lohse,† and Karl-Norbert Klotz†,‡

Dipartimento di Scienze Chimiche, Università di Camerino, 62032 Camerino, Italy, and Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 6900 Heidelberg, FRG. Received August 6, 1991

In the search for more selective A2-receptor agonists and on the basis that appropriate substitution at C2 is known to impart selectivity for A2 receptors, 2-alkynyladenosines **2a–d** were resynthesized and evaluated in radioligand binding, adenylate cyclase, and platelet aggregation studies. Binding of [^{3}H]NECA to A2 receptors of rat striatal membranes was inhibited by compounds **2a–d** with K_i values ranging from 2.8 to 16.4 nM. 2-Alkynyladenosines also exhibited high-affinity binding at solubilized A2 receptors from human platelet membranes. Competition of 2-alkynyladenosines **2a–d** for the antagonist radioligand [^{3}H]DPCPX and for the agonist [^{3}H]CCPA gave K_i values in the nanomolar range, and the compounds showed moderate A2 selectivity. In order to improve this selectivity, the corresponding 2-alkynyl derivatives of adenosine-5'-N-ethyluronamide **8a–d** were synthesized and tested. As expected, the 5'-N-ethyluronamide derivatives retained the A2 affinity whereas the A1 affinity was attenuated, resulting in an up to 10-fold increase in A2 selectivity. A similar pattern was observed in adenylate cyclase assays and in platelet aggregation studies. A 30- to 45-fold selectivity for platelet A2 receptors compared to A1 receptors was found for compounds **8a–c** in adenylate cyclase studies.

Adenosine appears to mediate a wide variety of physiological functions including vasodilatation, vasoconstriction in the kidney, cardiac depression, inhibition of lipolysis, inhibition of platelet aggregation, inhibition of lymphocyte functions, inhibition of insulin release and potentiation of glucagon release in the pancreas, inhibition of neurotransmitter release from nerve endings, stimulation of steroidogenesis, and potentiation of histamine release from mast cells.[2] Many of its effects can be attributed to the action at receptors located on the cell surface, which are mediated by at least two extracellular receptors divided into two major subtypes, called A1 and A2.[3]

At A1 receptors the most active analogues are N6-substituted adenosines, whereas at A2 receptors the most active compounds are adenosine-5'-N-alkyluronamides. We recently reported the synthesis of N6-substituted 1-deazaadenosines,[4] and of 2-chloro-N6-cyclopentyladenosine (CCPA) which proved to be an agonist with high affinity and approximately 10 000-fold selectivity for A1 adenosine receptors.[5,6]

(1) A preliminary account of this work was presented at the International Symposium on Pharmacology of Purinergic Receptors-IUPHAR Satellite Symposium, Noordwijk (The Netherlands), 6–8 July, 1990.

(2) Stone, T. W. Purine receptors and their pharmacological roles. *Advances in Drug Research*; Academic Press Limited: New York, 1989; Vol. 18, pp 291–429.

(3) (a) Van Calker, D.; Muller, M.; Hamprecht, B. Adenosine regulates via two different types of receptors the accumulation of cyclic AMP in cultured brain cells. *J. Neurosci.* 1979, *33*, 999–1005. (b) Londos, C.; Cooper, D. M. F.; Wolff, J. Subclasses of external adenosine receptors. *Proc. Natl. Acad. Sci. U.S.A.* 1980, *77*, 2551–2554. (c) Daly, J. W. Adenosine receptors: targets for future drugs. *J. Med. Chem.* 1982, *25*, 197–207. (d) Burnstock, G.; Buckley, N. J. The classification of receptors for adenosine and adenine nucleotides. In *Methods in Pharmacology. Methods Used in Adenosine Research*; Paton, D. M., Ed.; Plenum: New York, 1985; Vol. 6, pp 193–212. (e) Olsson, R. A.; Pearson, J. D. Cardiovascular purinoceptors. *Physiol. Rev.* 1990, *70* (3), 761–845. (f) Kennedy, C. P1- and P2-purinoceptor subtypes: an update. *Arch. Int. Pharmacodyn.* 1990, *303*, 30–50.

†Universität Heidelberg.
‡Present address: Dept. of Chemistry, Montana State University, Bozeman, MT 59717.

Scheme I

Table I. 2-Alkynyl Derivatives of Adenosine (2a–d) and Adenosine-5'-*N*-ethyluronamide (8a–d) from Scheme I

compd	R	chromatog solvent	yield, %	mp, °C[a]	formula[b]
2a	$(CH_2)_2CH_3$	$CHCl_3-cC_6H_{12}-MeOH$ (78:10:12)	83	118–120[c]	$C_{15}H_{19}N_5O_4$
2b	$(CH_2)_3CH_3$	$C_6H_6-AcOEt-MeOH$ (60:32:8)	84	115–117[c]	$C_{16}H_{21}N_5O_4$
2c	$(CH_2)_4CH_3$	$CHCl_3-C_6H_6-MeOH$ (60:35:5)	70	110–112[c]	$C_{17}H_{23}N_5O_4$
2d	$(CH_2)_5CH_3$	$CHCl_3-MeOH$ (90:10)	78	111–113[c]	$C_{18}H_{25}N_5O_4$
8a	$(CH_2)_2CH_3$	$CHCl_3-C_6H_{14}-MeOH$ (60:28:12)	70	137–139	$C_{17}H_{22}N_6O_4$
8b	$(CH_2)_3CH_3$	$CHCl_3-MeOH$ (92:8)	70	135–137	$C_{18}H_{24}N_6O_4$
8c	$(CH_2)_4CH_3$	$CHCl_3-MeOH$ (90:10)	65	196–198	$C_{19}H_{26}N_6O_4$
8d	$(CH_2)_5CH_3$	$CHCl_3-MeOH$ (90:10)	68	145–147	$C_{20}H_{28}N_6O_4$

[a] Uncorrected. [b] All compounds had satisfactory C, H, N, microanalyses and were within 0.4% of the theoretical value. All compounds exhibited ^{1}H NMR spectra consistent with the assigned structures. [c] Reference 12b.

On the other hand, the prototypical A₂ agonist adenosine-5'-*N*-ethyluronamide (NECA) showed little or no A₂ selectivity.[7] In the search for more selective A₂ receptor agonists and on the basis that appropriate substitution at C2 is known to impart selectivity for A₂ receptors,[7-11] 2-alkynyladenosines 2a–d[12] and the corresponding 2-alkynyl derivatives of adenosine-5'-*N*-ethyluronamide 8a–d were synthesized (Scheme I) and evaluated in radioligand binding, adenylate cyclase, and platelet aggregation studies.

(4) Cristalli, G.; Grifantini, M.; Vittori, S.; Klotz, K.-N.; Lohse, M. J. Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. *J. Med. Chem.* **1988**, *31*, 1179–1183.

(5) Lohse, M. J.; Klotz, K.-N.; Schwabe, U.; Cristalli, G.; Vittori, S.; Grifantini, M. 2-Chloro-N⁶-cyclopentyladenosine: a highly selective agonist at A₁ adenosine receptors. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1988**, *337*, 687–689.

(6) Klotz, K.-N.; Lohse, M. J.; Schwabe, U.; Cristalli, G.; Vittori, S.; Grifantini, M. 2-Chloro-N⁶-[³H]cyclopentyladenosine ([³H]CCPA): a high affinity agonist radioligand for A₁ adenosine receptors. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1989**, *340*, 679–683.

(7) Bruns, R. F.; Lu, G. H.; Pugsley, T. A. Characterization of the A₂ adenosine receptor labeled by [³H]NECA in rat striatal membranes. *Mol. Pharmacol.* **1986**, *29*, 331–346.

(8) Matsuda, A.; Ueda, T. The synthesis, mutagenic and pharmacological activities of 2-carbon-substituted adenosines. *Nucleosides Nucleotides* **1987**, *6*, 85–94.

(9) Ueeda, M.; Thompson, R. D.; Arroyo, L. H.; Olsson, R. A. 1-Alkoxyadenosines: potent and selective agonists at the coronary artery A₂ adenosine receptor. *J. Med. Chem.* **1991**, *34*, 1334–1339.

(10) Ueeda, M.; Thompson, R. D.; Arroyo, L. H.; Olsson, R. A. 2-Aralkoxyadenosines: potent and selective agonists at the coronary artery A₂ adenosine receptor. *J. Med. Chem.* **1991**, *34*, 1340–1344.

(11) (a) Hutchison, A. J.; Webb, R. L.; Oei, H. H.; Ghai, G. R.; Zimmerman, M. B.; Williams, M. [³H]CGS 21680, a selective A₂ adenosine receptor agonist directly labels A₂ receptors in rat brain. *J. Pharmacol. Exp. Ther.* **1989**, *251*, 888–893. (b) Hutchison, A. J.; Williams, M.; de Jesus, R.; Yokoyama, R.; Oei, H. H.; Ghai, G. R.; Webb, R. L.; Zoganas, H. C.; Stone, G. A.; Jarvis, M. F. 2-(Arylalkylamino)adenosine-5'-uronamides: a new class of highly selective adenosine A₂ receptor ligands. *J. Med. Chem.* **1990**, *33*, 1919–1924.

(12) (a) Matsuda, A.; Shinozaki, M.; Miyasaka, T.; Machida, H.; Abiru, T. Palladium-catalized cross-coupling of 2-iodo-adenosine with therminal alkynes: synthesis and biological activities of 2-alkynyladenosines. *Chem. Pharm. Bull.* **1985**, *33*, 1766–1769. (b) Miyasaka, T.; Matsuda, A.; Abiru, T.; Machida, H. Antihypertensive agents comprising 2-alkynyladenosines as active ingredients. Eur. Pat. 0 219 876 A2, 1987. (c) Abiru, T.; Yamaguki, T.; Watanabe, Y.; Kogi, K.; Aihara, K.; Matsuda, A. The antihypertensive effect of 2-alkynyl-adenosines and their selective affinity for adenosine A₂ receptors. *Eur. J. Pharmacol.* **1991**, *196*, 69–76.

Chemistry

The synthesis of 2-alkynyladenosines **2a–d**[12a] and of 2-alkynyl derivatives of adenosine-5'-*N*-ethyluronamide **8a–d** was accomplished by the reactions described in Scheme I. The synthesis of compounds **2a–d** was carried out by a modification of the palladium-catalyzed cross-coupling reaction reported by Matsuda et al.[12a] Treatment of a solution of 2-iodoadenosine (**1**)[13] in dry acetonitrile and triethylamine with cuprous iodide, PdCl₂, triphenylphosphine, and the appropriate terminal alkyne, at room temperature for 24 h under an atmosphere of N₂, effected complete conversion of the iodonucleoside to the alkynyl derivatives **2a–d** (Table I).

The synthesis of the NECA derivatives **8a–d** was accomplished by a similar cross-coupling reaction between the appropriate terminal alkynes and the new nucleoside *N*-ethyl-1'-deoxy-1'-(6-amino-2-iodo-9*H*-purin-9-yl)-β-D-ribofuranuronamide (**7**).

The synthesis of *N*-ethyl-1'-deoxy-1'-(6-amino-2-iodo-9*H*-purin-9-yl)-β-D-ribofuranuronamide (**7**) is reported in Scheme I. Reaction at room temperature of 2-iodo-adenosine (**1**)[13] with acetone in the presence of *p*-toluenesulfonic acid as a catalyst gave 6-amino-2-iodo-9-(2',3'-*O*-isopropylidene-β-D-ribofuranosyl)-9*H*-purine (**3**). This compound was oxidized with KMnO₄ in aqueous base to afford the carboxylic acid **4** in 76% yield. Cleavage of the acetonide of **4** with 50% formic acid at 80 °C gave 1'-deoxy-1'-(6-amino-2-iodo-9*H*-purin-9-yl)-β-D-ribofuranuronic acid (**5**) in 85% yield.

Treatment of the carboxylic acid **5** with SOCl₂ in absolute ethanol at room temperature overnight afforded the ester **6**, which reacted with dry ethylamine at −20 °C to give the desired *N*-ethyl-1'-deoxy-1'-(6-amino-2-iodo-9*H*-purin-9-yl)-β-D-ribofuranuronamide (**7**).

Treatment of a solution of compound **7** in dry acetonitrile and triethylamine with cuprous iodide, PdCl₂, triphenylphosphine, and the appropriate terminal alkyne gave the 2-alkynyladenosine-5'-*N*-ethyluronamide derivatives **8a–d** in good yield.

Biological Evaluation and Discussion

The effects of alkynyladenosines on adenosine receptors were tested using both radioligand binding techniques and functional assays. Affinities for A₂ receptors were determined in radioligand competition assays for the receptors of rat striatum and human platelets using [³H]NECA as the radioligand and *N⁶*-cyclopentyladenosine (CPA) in order to saturate A₁ receptors. To allow determination of affinities for platelet A₂ receptors, the receptors were separated from nonreceptor binding sites by chromatographic procedures as described.[14] Affinities for A₁ receptors were determined in radioligand competition assays for the receptors of rat brain using the agonist [³H]CCPA and the antagonist [³H]DPCPX as radioligands. NECA, CPA, and *N⁶*-[(*R*)-(−)-1-methyl-2-phenethyl]adenosine (*R*-PIA) were used as reference compounds. Functional activity at adenosine receptors was determined in adenylate cyclase assays by measuring A₁ receptor-mediated inhibition in rat fat cell membranes and A₂ receptor-mediated stimulation in human platelet membranes.[15]

Affinities of 2-alkynyladenosines for the A₂ receptors (Table II) were in the range of 2–40 nM for both receptor preparations. In the case of the rat striatal receptors highest affinities were found for chain lengths of six and seven (compounds **2b** and **2c**), whereas for the human platelet receptors the highest affinities were found for the shortest chain lengths (compounds **2a** and **2b**). All compounds had an A₁ receptor affinity (high-affinity component) of about 20 nM, regardless of the radioligand used. As a consequence, most compounds were moderately A₂-selective (Table II). The A₂ selectivity was highest for a chain length of seven in the case of the rat striatum receptor (∼10-fold), and a chain length of five in the case of the human platelet receptor (2–3-fold). Shortly after a preliminary presentation of our results,[1] Abiru et al.[11c] reported binding data for compounds **2b** and **2d**. Their data agree reasonably with our data: there is a trend toward lower A₁ affinities and higher A₂ affinities, so that in their report A₂ selectivity is somewhat higher. We think these are just variations between laboratories, since also the reference compounds showed the same trend, including their *K*_D values for the radioligand.

A very similar pattern was observed in adenylate cyclase assays comparing A₁ receptors in rat fat cells with A₂ receptors in human platelets (Table III). Again, all compounds had identical affinities for A₁ receptors (IC₅₀ values of 2–3 μM), but compounds with shorter chain lengths had higher affinities for the platelet A₂ receptors. Remarkably, all 2-alkynyladenosines **2a–d** were only 60–70% effective (*E*_max, Table III), resulting in partial agonists at A₂ receptors. The A₂ selectivities calculated from adenylate cyclase studies (Table III) were about 10-fold higher than those determined by radioligand binding. This phenomenon has been observed previously by other groups as well as ourselves.[5,7] It appears to be due firstly to the previously reported discrepancy between the high-affinity state of A₁ receptors for agonists and the corresponding IC₅₀ values in inhibiting adenylate cyclase[16]—a difference much less pronounced for A₂ receptors—and secondly to complexities in functional assays as a consequence of receptor reserves.[17] The A₂ selectivity was again highest for the shortest chain length.

In order to improve this A₂ selectivity, the corresponding 2-alkynyl derivatives of NECA **8a–d** were synthesized and tested (Tables II and III). The overall pattern of results are similar to the one obtained above, but the A₂ selectivity was indeed improved. This resulted in compounds **8b** and **8c** that showed an almost 40-fold selectivity for the A₂ receptors of rat striatum compared to A₁ receptors of rat brain. Compound **8b** also had a 10–20-fold selectivity for the A₂ receptors of human platelets. A 30–45-fold selectivity for platelet A₂ receptors compared to A₁ receptors was found for compounds **8a–c** in adenylate cyclase studies (Table III).

Platelet aggregation studies confirmed the previous results. 2-Hexynyl-NECA (**8b**) was the most active inhibitor of ADP-induced platelet aggregation with an IC₅₀ value of 50 nM, compared to the parent compound NECA with

(13) Nair, V.; Richardson, S. G. Modification of nucleic acid bases via radical intermediates: synthesis of dihalogenated purine nucleosides. *Synthesis* **1982**, 670–672.

(14) Lohse, M. J.; Elger, B.; Lindenborn-Fotinos, J.; Klotz, K.-N.; Schwabe, U. Separation of solubilized A₂ adenosine receptors of human platelets from non-receptor [³H]NECA binding sites by gel filtration. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1988**, *337*, 64–68.

(15) Klotz, K.-N.; Cristalli, G.; Grifantini, M.; Vittori, S.; Lohse, M. J. Photoaffinity labeling of A₁-adenosine receptors. *J. Biol. Chem.* **1985**, *260*, 14659–14664.

(16) Lohse, M. J.; Klotz, K.-N.; Schwabe, U. Agonist photoaffinity labeling of A₁ adenosine receptors: persistent activation reveals spare receptors. *Mol. Pharmacol.* **1986**, *30*, 403–409.

(17) Lohse, M. J.; Klotz, K.-N.; Schwabe, U. Mechanisms of A₂ adenosine receptor activation. I. Blockade of A₂ adenosine receptors by photoaffinity labeling. *Mol. Pharmacol.* **1991**, *39*, 517–523.

Table II. Competition of the 2-Alkynyl Derivatives of Adenosine and NECA for Radioligands at A1 and A2 Receptors

compd	R	R1	A1 [³H]DPCPX high affinity	A1 [³H]DPCPX low affinity	A1 [³H]CCPA K_i (nM)[a]	A2 [³H]NECA striatum	A2 [³H]NECA platelet	A2 selectivity (K_iA1/K_iA2) DPCPX/ striatum	A2 selectivity (K_iA1/K_iA2) CCPA/ striatum
2a	$(CH_2)_2CH_3$	CH_2OH	16.0 10.0–25.5	849 523–1380	21.5 11.2–41.6	16.4 8.0–33.8	7.3 2.6–20.6	1	1
2b	$(CH_2)_3CH_3$	CH_2OH	12.5 5.6–27.9	633 253–1580	15.9 4.7–53.2	3.6 2.2–5.9	8.1 3.8–17.4	3	4
2c	$(CH_2)_4CH_3$	CH_2OH	32.2 13.4–77.5	1216 777–1910	28.4 17.9–45.2	2.8 1.9–4.2	20.8 17.4–24.9	11	10
2d	$(CH_2)_5CH_3$	CH_2OH	19.6 6.5–59.1	823 484–1400	25.2 11.3–56.6	6.3 4.2–9.5	39.9 10.9–145	3	4
8a	$(CH_2)_2CH_3$	CONHEt	33.0 18.0–60.0	1620 1150–2260	40.8 27.2–61.1	19.5 4.1–93.3	12.6 4.2–37.9	2	2
8b	$(CH_2)_3CH_3$	CONHEt	136 95–195	3160 1420–7030	43.9 38.1–50.6	3.8 1.5–9.9	5.7 4.3–7.5	36	12
8c	$(CH_2)_4CH_3$	CONHEt	171 146–201	2910 1060–7990	89 69–114	4.7 2.4–9.3	37.1 17.3–79.5	36	19
8d	$(CH_2)_5CH_3$	CONHEt	67 27.0–164	2940 2040–4240	64.4 40.5–102.3	14.8 8.2–26.7	159 59–429	5	4
NECA			11 7.0–17	650 420–1000	8.2 6.2–10.9	22 20–25	70 55–89	0.5	0.4
R-PIA			1.0 0.8–1.3	200 160–250	1.3 1.1–1.6	730 690–770	1700 1100–2600	0.001	0.002
CPA			0.8 0.5–1.3	130 90–190	0.8 0.6–1.1	2000 1400–2900	2400 1300–4400	0.0004	0.0004

[a] For A1 receptors K_i values were determined from competition for [³H]DPCPX (antagonist) and [³H]CCPA (agonist) binding at rat brain membranes. K_i values for A2 receptors were determined at rat striatal membranes in the presence of 50 nM CPA and at solubilized receptors from human platelet membranes. Data are means from three to six independent experiments with 95% confidence limits. [b] A2 selectivity ratios were calculated with high-affinity K_i values from competition for [³H]DPCPX binding at rat brain membranes and K_i values from competition for [³H]NECA binding at rat striatal membranes. For comparison A2 selectivity was also determined with K_i values from competition for [³H]CCPA binding and [³H]NECA binding.

Table III. Effects of the 2-Alkynyl Derivatives of Adenosine and NECA on Adenylate Cyclase[a]

compd	R	R1	A1 IC_{50}, nM	A2 EC_{50}, nM	A2 select (IC_{50}/EC_{50})	E_{max}, %
2a	$(CH_2)_2CH_3$	CH_2OH	3000 1150–7840	127 95–171	24	65
2b	$(CH_2)_3CH_3$	CH_2OH	2300 1320–4000	128 90–182	19	65
2c	$(CH_2)_4CH_3$	CH_2OH	3380 1200–9520	414 289–592	8	65
2d	$(CH_2)_5CH_3$	CH_2OH	2910 1030–8200	681 240–1930	4	65
8a	$(CH_2)_2CH_3$	CONHEt	2700 2010–3630	62 38–100	44	100
8b	$(CH_2)_3CH_3$	CONHEt	4380 1990–9640	105 48–229	42	100
8c	$(CH_2)_4CH_3$	CONHEt	13090 6750–25400	388 277–543	34	100
8d	$(CH_2)_5CH_3$	CONHEt	13500 7900–23100	585 479–714	23	100

[a] All compounds inhibited adenylate cyclase via A1 receptors in rat fat cell membranes to the same degree as the full agonist CCPA, and the maximal inhibition was 45 ● 4.3% ($n = 9$, ±SEM). The maximal NECA stimulation of adenylate cyclase via A2 receptors in human platelet membranes amounted to 319 ± 16% ($n = 7$, ±SEM). Compounds 2a–d are only partial agonists ($E_{max} = 65\%$), whereas 8a–d are full agonists ($E_{max} = 100\%$). Values are means and SEM's or 95% confidence limits of three to four independent determinations.

Figure 1. Dose–response curves of inhibitory effect of 2-hexynyl-NECA (■) and NECA (□) on human platelet aggregation induced by ADP. Data represent means of at least three independent determinations.


Figure 2. Influence of methylene groups in the chain of compounds 8a–d on A_2 selectivity. Comparison of A_2 selectivity in the binding of DPCPX/striatum (●), CCPA/striatum (O), DPCPX/platelet (■), and CCPA/platelet (□).

an IC_{50} of 500 nM (Figure 1).

The compounds described here seem to be capable not only of distinguishing between A_1 and A_2 receptors, but also between the A_2 receptors of rat brain and human platelets (Figure 2). 2-Heptynyl-NECA (8c) and 2-octynyl-NECA (8d) have about a 10-fold higher affinity for the rat striatal A_2 receptor. Further studies will have to address the question whether these are only species differences, or whether they represent true A_2 receptor subtypes.

Agonists with high affinity for A_2 receptors have already been described by Bridges et al.[18a] These are adenosine and NECA derivatives with bulky N^6-substituents, in particular diphenylethyl substituents.[18b] In a direct comparison in our laboratory, these compounds had only little if any A_2 receptor selectivity (data not shown). Attempts to increase A_2 selectivity by the combination of appropriate modifications at N^6 and C5' were not very successful.[19]

Williams and co-workers[11] have recently described a series of substituted 2-amino derivatives of NECA that show even higher selectivity for A_2 receptor, but have at least 2-fold lower affinities than compounds 8b and 8c described here. The high affinities of the compounds described here together with reasonable selectivities should make them useful tools for the characterization of adenosine receptors.

Experimental Section

Chemistry. Melting points were determined with a Büchi apparatus and are uncorrected. ¹H NMR spectra were obtained with a Varian VX 300 MHz spectrometer. IR spectra were recorded on a Perkin-Elmer Model 297 spectrophotometer. TLC were carried out on pre-coated TLC plates with silica gel 60 F-254 (Merck). For column chromatography, silica gel 60 (Merck) was used. Microanalytical results are within ±0.4% of theoretical values.

Preparation of 2-Alkynyladenosines (2a–d). To a solution of 2-iodoadenosine[13] (1) (1.27 mmol) in 10 mL of dry acetonitrile and 10 mL of triethylamine under an atmosphere of N_2 were added 18.6 mg (0.0976 mmol) of cuprous iodide, 12 mg (0.0672 mmol) of $PdCl_2$, and 39 mg (0.149 mmol) of triphenylphosphine. To the mixture was added the appropriate terminal alkyne (6.3 mmol), and the reaction mixture was stirred under an atmosphere of N_2 at room temperature for 24 h. The solvent was removed in vacuo, and the residue was chromatographed on a silica gel column, eluting with a suitable mixture of solvents (Table I) to give 2a–d as chromatographically pure solids. All of the spectral data for the compounds were compatible with the structures.

Preparation of 2-Alkynyladenosine-5'-N-ethyluronamides (8a–d). To a solution of N-ethyl-1'-deoxy-1'-(6-amino-2-iodo-9H-purin-9-yl)-β-D-ribofuranuronamide (7) (0.58 mmol) in 10 mL of dry acetonitrile and 5 mL of triethylamine under an atmosphere of N_2 were added 8.5 mg (0.0446 mmol) of cuprous iodide, 5.5 mg (0.0308 mmol) of $PdCl_2$, and 17.8 mg (0.069 mmol) of triphenylphosphine. To the mixture was added the appropriate terminal alkyne (2.9 mmol), and the reaction mixture was stirred under an atmosphere of N_2 at room temperature for 16 h. The solvent was removed in vacuo, and the residue was chromatographed on a silica gel column, eluting with a suitable mixture of solvents (Table I) to give 8a–d as chromatographically pure solids. All of the spectral data for the compounds were compatible with the structures.

6-Amino-2-iodo-9-(2',3'-O-isopropylidene-β-D-ribofuranosyl)-9H-purine (3). To a solution of 2 g (5.08 mmol) of 2-iodoadenosine (1)[13] in 100 mL of acetone was added 9.6 g of p-toluenesulfonic acid. The reaction mixture was stirred at room temperature for 1 h and then, after the addition of 15 g of $NaHCO_3$, stirred again for 3 h. The solid was removed and washed two times with EtOAc, and the filtrate was concentrated to dryness. The residue was flash chromatographed on a silica gel column, eluting with $CHCl_3$–MeOH (99:1) to give 1.62 g (74%) of 3 as a solid: mp 185–187 °C; ¹H NMR (Me_2SO-d_6) δ 1.33 and 1.54 (s, 3 H each, $C(CH_3)_2$), 3.53 (m, 2 H, CH_2-5'), 4.19 (m, 1 H, H-4'), 5.07 (t, 1 H, OH), 4.93 (m, 1 H, H-3'), 5.27 (m, 1 H, H-2'), 6.05 (d, J = 2.5 Hz, 1 H, H-1'), 7.76 (s, 2 H, NH_2), 8.28 (s, 1 H, H-8). Anal. ($C_{13}H_{16}IN_5O_4$) C, H, N.

1'-Deoxy-1'-(6-amino-2-iodo-9H-purin-9-yl)-2',3'-O-isopropylidene-β-D-ribofuranuronic Acid (4). To a stirred solution of 1.6 g (3.7 mmol) of 3 in 200 mL of H_2O were added 0.60 g of KOH and, dropwise, a solution of 1.70 g (10.8 mmol) of $KMnO_4$ in 50 mL of H_2O. The mixture was set aside in the dark at room temperature for 20 h. The reaction mixture was cooled to 5–10 °C and then decolorized by a solution of 4 mL of 30% H_2O_2 in 16 mL of water, while the temperature was maintained under 10 °C using an ice–salt bath. The mixture was filtered through Celite, and the filtrate was concentrated in vacuo to about 15 mL and then acidified to pH 4 with 2 N HCl. The resulting precipitate was filtered off and successively washed with water,

(18) (a) Bridges, A. J.; Moos, W. H.; Szotek, D. L.; Trivedi, B. K.; Bristol, J. A.; Heffner, T. G.; Bruns, R. F.; Downs, D. A. N^6-(2,2-Diphenylethyl)adenosine a novel adenosine receptor agonist with antipsychotic-like activity. *J. Med. Chem.* **1987**, *30*, 1709–1711. (b) Bridges, A. J.; Bruns, R. F.; Ortwine, D. F.; Priebe, S. R.; Szotek, D. L.; Trivedi, B. K. N^6-[2-(3,5-Dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A_2 receptor. *J. Med. Chem.* **1988**, *31*, 1282–1285.

(19) Olsson, R. A.; Kusachi, S.; Thompson, R. D.; Ukena, D.; Padgett, W.; Daly, D. T. N^6-Substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A_1 and A_2 adenosine receptors. *J. Med. Chem.* **1986**, *29*, 1683–1689.

acetone, and ether to give 1.25 g (76%) of 4 as a white solid: mp 187–190 °C; IR ν_{max} 1590, 1640 cm^{-1} (COOH); ^{1}H NMR (Me$_2$SO-d_6) δ 1.33 and 1.49 (s, 3 H each, C(CH$_3$)$_2$), 4.64 (s, 1 H, H-4'), 5.35 (d, $J_{3',2'}$ = 5.6 Hz, 1 H, H-3'), 5.41 (d, $J_{2',3'}$ = 5.6 Hz, 1 H, H-2'), 6.23 (s, 1 H, H-1'), 7.53 (s, 1 H, COOH), 7.67 (s, 2 H, NH$_2$), 8.17 (s, 1 H, H-8). Anal. (C$_{13}$H$_{14}$IN$_5$O$_5$) C, H, N.

1'-Deoxy-1'-(6-amino-2-iodo-9H-purin-9-yl)-β-D-ribofuranuronic Acid (5). A solution of 1.72 g (3.85 mmol) of 4 in 80 mL of 50% HCOOH was stirred at 80 °C for 1.5 h. The reaction mixture was evaporated in vacuo, the residue was dissolved in water, and the solution was evaporated. This process was repeated several times until there was no odor of formic acid in the residue. Recrystallization from water yielded 1.33 g (85%) of 5 as a white solid: mp 217–220 °C dec; ^{1}H NMR (Me$_2$SO-d_6) δ 4.28 (m, 1 H, H-3'), 4.41 (d, J = 2.1 Hz, 1 H, H-4'), 4.81 (m, 1 H, H-2'), 5.95 (d, J = 6.7 Hz, 1 H, H-1'), 7.78 (s, 2 H, NH$_2$), 8.38 (s, 1 H, H-8), 12.98 (br s, 1 H, COOH). Anal. (C$_{10}$H$_{10}$IN$_5$O$_5$) C, H, N.

Ethyl 1'-Deoxy-1'-(6-amino-2-iodo-9H-purin-9-yl)-β-D-ribofuranuronate (6). To a cooled (5 °C) and stirred solution of 1.29 g (3.17 mmol) of 5 in 150 mL of absolute ethanol was added dropwise 1.15 mL of ice-cooled SOCl$_2$. The mixture was stirred at room temperature overnight and then brought to pH 8 with saturated aqueous NaHCO$_3$. The mixture was filtered, and the filtrate was concentrated in vacuo. Recrystallization of the residue from water–ethanol (1:1) gave 900 mg (65%) of 6 as a white solid: mp 221–223 °C dec; IR ν_{max} 1728 cm^{-1} (COOEt); ^{1}H NMR (Me$_2$SO-d_6) δ 1.21 (t, 3 H, CH$_2$CH$_3$), 4.18 (q, 2 H, CH$_2$CH$_3$), 4.34 (m, 1 H, H-3'), 4.47 (s, 1 H, H-4'), 4.58 (m, 1 H, H-2'), 5.96 (d, J = 6.7 Hz, 1 H, H-1'), 7.74 (s, 2 H, NH$_2$), 8.33 (s, 1 H, H-8). Anal. (C$_{12}$H$_{14}$IN$_5$O$_5$) C, H, N.

N-Ethyl-1'-Deoxy-1'-(6-amino-2-iodo-9H-purin-9-yl)-β-D-ribofuranuronamide (7). A mixture of 620 mg of 6 and 18 mL of dry ethylamine was stirred at –20 °C for 3 h and then at room temperature overnight. The reaction mixture was diluted with absolute ethanol, and the precipitated product was filtered off and washed with dry ether to give 530 mg (85%) of 7 as a pure solid: mp 232–234 °C; IR ν_{max} 1637, 1560 cm^{-1} (C=O, amide); ^{1}H NMR (Me$_2$SO-d_6) δ 1.06 (t, 3 H, CH$_2$CH$_3$), 3.28 (m, 2 H, CH$_2$CH$_3$), 4.16 (m, 1 H, H-3'), 4.31 (d, J = 2.1 Hz, 1 H, H-4'), 4.58 (m, 1 H, H-2'), 5.91 (d, 1 H, J = 7.3 Hz, H-1'), 7.79 (s, 2 H, NH$_2$), 8.15 (t, 1 H, NH), 8.40 (s, 1 H, H-8). Anal. (C$_{12}$H$_{15}$IN$_6$O$_4$) C, H, N.

Biological Studies. Membrane Preparation. Membranes from rat brain and rat striatum were prepared as described.[20] Human platelet membranes were prepared according to the method of Hoffman et al.[21] A$_2$ receptors from platelet membranes were solubilized as described recently.[14] Rat fat cells were isolated as described by Honnor et al.,[22] and their membranes were prepared according to MeKeel and Jarett.[23]

Radioligand Binding Assays. Radioligand binding at A$_1$ receptors from rat brain membranes was measured as described in detail for the antagonist [^{3}H]DPCPX[24] and the agonist [^{3}H]CCPA.[6] [^{3}H]NECA was used to measure A$_2$ receptor binding in rat striatal membranes, according to the procedure of Bruns et al.,[7] in a total value of 250 μL containing 50 μg of protein. A$_1$ receptor was saturated with 50 nM cyclopentyladenosine. Binding to solubilized A$_2$ receptors from human platelets was performed with [^{3}]NECA as described.[14]

Adenylate Cyclase Assay. Inhibition of adenylate cyclase activity via A$_1$ receptors was measured in rat fat cell membranes in the presence of 10 μM forskolin, and stimulation of adenylate cyclase via A$_2$ receptors was determined in human platelet membranes.[15]

Data Analysis. Concentration–response curves containing at least seven different concentrations in duplicate were fitted by nonlinear regression to the Hill equation as described.[16] Binding data were analyzed by the curve-fitting program SCATFIT according to a one-site model.[25] A two-site model was assumed if the fit was significantly improved ($p < 0.01$, F test).

Platelet Aggregation Assay. Platelet aggregation was measured by modification of the method of Born and Cross[4,26] using a Platelet Aggregation Profiler Model Pap-3 (Bio Data Corp.). The aggregative agent ADP was purchased from Sigma Chemical Co. Blood was obtained by venipuncture in the forearms of apparently healthy humans and collected in polyethylene tubes containing a 1:9 volume of 3.8% sodium citrate. Platelet-rich plasma (PRP) was obtained by centrifugation at 1200 rpm for 15 min, while platelet-poor plasma (PPP) was obtained by centrifugation at 4500 rpm for 20 min.

A 20-μL aliquot of the test sample, dissolved in 0.5% of DMSO in water, was added to a cuvette containing 470 μL of PRP, and a 20 μL aliquot of 0.5% of DMSO in water was added to the test control. The cuvette was placed in the aggregation meter and allowed to incubate at 37 °C for 5 min, after which 10 μL of 2.5 × 10^{-6} ADP (final concentration) was added to the PRP.

The percent inhibition of aggregation by a test compound was calculated by dividing the maximal deflection in the optical density curve in the presence of the compound by that observed in the control and then multiplying by 100. Data represent means of at least three independent determinations.

(20) Lohse, M. J.; Lenschow, V.; Schwabe, U. Two affinity states of Ri adenosine receptors in brain membranes: analysis of guanine nucleotide and temperature effects on radioligand binding. *Mol. Pharmacol.* **1984**, *26*, 1–9.

(21) Hoffman, B. B.; Michel, T.; Brenneman, T. B.; Lefkowitz, R. Interactions of agonists with platelet α_2-adrenergic receptors. *J. Endocrinol.* **1982**, *110*, 926–932.

(22) Honnor, R. C.; Dhillon, G. S.; Londos, C. Cyclic AMP and lipolysis in rat adipocytes. Cell preparation, manipulation and predictability in behavior. *J. Biol. Chem.* **1985**, *260*, 15122–15129.

(23) McKeel, D. W.; Jarett, L. Preparation and characterization of a plasma membrane fraction from isolated fat cells *J. Cell. Biol.* **1970**, *44*, 417–432.

(24) Lohse, M. J.; Klotz, K.-N.; Lindenborn-Fotinos, J.; Reddington, M.; Schwabe, U.; Olsson, R. A. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) a selective high affinity radioligand for A$_1$ adenosine receptors. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1987**, *336*, 204–210.

(25) De Lean, A.; Hancock, A. A.; Lefkowitz, R. J. Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. *Mol. Pharmacol.* **1982**, *21*, 5–16.

(26) Born, G. V. R.; Cross, M. J. The aggregation of blood platelets. *J. Physiol.* **1963**, *168*, 178–195.